Ayala Pharmaceuticals Inc (AYLA)

[crudeoil24]

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The Company's portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway using gamma secretase inhibitors (GSIs). AL101 and AL102 are designed to address the underlying key drivers of tumor growth. The Company is evaluating AL101 as a monotherapy in an open-label Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma (R/M ACC), for patients bearing Notch-activating mutations. The Company also developing AL102 for the treatment of other rare indications including T-ALL, an aggressive, rare form of T-cell specific leukemia. The Company is also conducting its ongoing Phase II ACCURACY trial for the treatment of R/M ACC in subjects with progressive disease and Notch-activating mutations.